CompletedPhase 4

COVID-19 Vaccination of Immunodeficient Persons (COVAXID)

Sweden539 participantsStarted 2021-02-23

Plain-language summary

The study is designed as an open, non-randomized, phase IV cohort study in which the mRNA vaccine Comirnaty will be given in two doses. Analyses will be performed on blood and saliva, investigating humoral and cellular vaccine responses. Occurence of local or systemic reactogenicity will be evaluated, as well as adverse events. The study will include persons with primary or secondary immunosuppressive disorders, as well as immunocompetent persons, with the aim of investigating if the immune responses after given Comirnaty mRNA vaccine against COVID-19.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Previous or ongoing Coronavirus Disease-19 (COVID-19).
✕. Coagulation disorders, other conditions associated with prolonged bleeding time or anticoagulant treatments, which according to the investigator contraindicate intramuscular injection. Conditions which can be corrected with measures such as platelet concentrate treatments, coagulation factors or other measures for people responsible for anticoagulants are not exclusion criteria.
✕. Planned to receive another vaccine within 14 days before the first dose of the study vaccine, or during the period from the first dose of the study vaccine up to 14 days after the second dose of the study vaccine, and vaccination with another vaccine which in the investigator's opinion cannot be planned outside these time periods
✕. Pregnancy or breast feeding.
✕. Hypersensitivity to the active substance or to any of the excipients contained in the vaccine
✕. Individuals who cannot understand the informed consent.
✕. Individuals who for other reasons are considered by investigators as not suitable for inclusion

What they're measuring

Assessment of Seroconversion, Defined as Development of Immunoglobulin G (IgG) Antibodies Against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) After Vaccination of 2 Doses in Seronegative Individuals.

Timeframe: 2 weeks after second dose of vaccine.

Trial details

NCT IDNCT04780659

SponsorKarolinska University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-10-15

Results submitted2025-09-09

View on ClinicalTrials.gov More Covid19 trials